REG - Haleon PLC - Divestment of NRT business outside US complete

HALEONAnnouncement

30/09/2024 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240930:nRSd2350Ga&default-theme=true

RNS Number : 2350G  Haleon PLC  30 September 2024

 

Divestment of the nicotine replacement therapy business outside of the US to
Dr. Reddy's completed

 

30 September 2024: Haleon plc ("Haleon") (LSE/NYSE: HLN) today announces that
it has completed the divestment of its nicotine replacement therapy ("NRT")
business outside of the US.

 

On 26 June 2024, Haleon announced that it had entered into an agreement to
sell its NRT business outside of the US to Dr. Reddy's Laboratories SA ("Dr.
Reddy's"), a wholly owned subsidiary of Dr. Reddy's Laboratories Limited for
total consideration of up to £500m (with additional proceeds from the
transfer of inventory), which comprises an upfront payment of £458m and
further deferred, performance-based consideration of up to £42m payable
during 2025 and H1 2026.

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                    Media

 Sonya Ghobrial          +44 7392 784784      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Gemma Thomas        +44 7985 175048
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISGCGDCDBXDGSG